Abstract: A fast and easy method was validated for simultaneous determination of ciprofloxacin hydrochloride monohydrate (CP), levofloxacin hemihydrate (LV), and N-acetylcysteine (NAC) in samples. The analysis was performed on a C 18 column (250 × 4.6 mm, 5 µm) (Inertsil ODS-3V) using an isocratic elution method with a mobile phase composed of 25 mM KH 2 PO 4 (pH 3.0) and methanol (72:28, v/v) at a flow rate of 1 mL/min. UV detection was performed at 214 nm for NAC and 293 nm for CP and LV. The method was validated for linearity, accuracy, precision (repeatability and reproducibility), specificity, sensitivity, and stability. The calibration study using several media demonstrated that the calibration curves were linear for all compounds in all media (R 2 >0.9993). The limit of detection was 0.098 µg/mL for CP, 0.049 µg/mL for LV, and 0.487 µg/mL for NAC. The limit of quantification was 0.328 µg/mL for CP, 0.165 µg/mL for LV, and 1.624 µg/mL for NAC. Precision and accuracy values of the method fulfilled the required limits. All these outcomes demonstrate that the validated HPLC method is appropriate for simultaneous analysis of CP, LV, and NAC in samples for content uniformity of dry powder inhaler and permeability studies.
Introduction
Cystic fibrosis (CF) is a life-shortening autosomal recessive genetic disease that can be caused by mutations in the gene that results in abnormally viscous secretions in various exocrine tissues, including the respiratory tract [1] [2] [3] [4] .
In CF, the fluidity of the mucus layer decreases, which is crucial for the clearance of bacteria and other microorganisms from the airways. Moreover, lower mucus secretion and reduced pH of airway surface liquid may cause inhibition of antimicrobial activity [3, 5] . Thus, recurrent bronchiectasis and infections, especially caused by Staphylococcus aureus and Pseudomonas aeruginosa, are the major reason for morbidity and mortality in CF [4] [5] [6] . Although there are various antibiotics administered orally and intravenously to treat lung infections in CF patients, inhalation is the most efficient administration route to directly reach the infection site [7, 8] .
Fluoroquinolone antibiotics are broad-spectrum synthetic drugs widely used for the treatment of lung infections [9] [10] [11] . Ciprofloxacin and levofloxacin were selected for this study as fluoroquinolone antibiotics. A mucolytic was added to the formulations to increase the effectiveness of antibiotics in CF treatment. The most important problem in the treatment of CF-associated infections is the difficulty of antibiotic penetration into the * Correspondence: loner@hacettepe.edu.tr This work is licensed under a Creative Commons Attribution 4.0 International License. dehydrated and viscous mucus layer in the lungs. Therefore, N-acetylcysteine (NAC) was chosen as a mucolytic agent to increase the penetration ability of ciprofloxacin and levofloxacin.
Content uniformity and permeability are some of the quality attributes considered for prepared dry powder inhalers (DPIs). To estimate the content uniformity and permeability values correctly, it is crucial to use a validated method with enough sensitivity, selectivity, accuracy, and precision for each compound in different matrixes. In this study, we aimed to validate an HPLC method for the simultaneous analysis of NAC in the presence of ciprofloxacin and levofloxacin in samples obtained from content uniformity and permeability studies.
Several HPLC methods are available in the literature for the determination of ciprofloxacin [12] [13] [14] , levofloxacin [15] [16] [17] , and NAC [18] [19] [20] individually in pharmaceutical formulations. There are studies in the literature where NAC was combined with ciprofloxacin hydrochloride monohydrate (CP) [21] [22] [23] [24] or levofloxacin hemihydrate (LV) [25, 26] . These studies were clinical or microbiological studies and unfortunately none of them included quantification of NAC or the fluoroquinolones. It is important to be able to detect not only fluoroquinolone antibiotics but also NAC since all of them are active pharmaceutical ingredients and have physiological effects on living organisms. Moreover, quantification of all active ingredients with a single method will be faster, efficient, and more cost-effective compared to separate analyses. For the analysis of ciprofloxacin, levofloxacin, and NAC, a short, sensitive, and fully validated analysis method is needed. In this study, simultaneous quantification of NAC and its combination with ciprofloxacin or levofloxacin was performed for the first time. The method was suitable for the analysis of ciprofloxacin, levofloxacin, and NAC in DPIs and permeability studies.
Materials and methods

Chemicals
CP, LV, and NAC were kindly provided by Neuland Labs. (Hyderabad, India). Methanol and potassium dihydrogen phosphate were purchased from Sigma Aldrich (St. Louis, MO, USA). Water was purified using a Milli-Q system (Millipore). All other chemicals were of analytical grade.
Instrumentation and chromatographic conditions
The HPLC system used for analysis was Agilent 1200 series (Germany). CP, LV, and NAC were separated using an Inertsil ODS-3V C 18 column (250 × 4.6 mm 5 µm; Japan). The HPLC system was operated at 40°C using a mobile phase consisting of 25 mM KH 2 PO 4 (pH 3.0) and methanol (72:28, v/v). The mobile phase was filtered through a 0.45-µm membrane filter, degassed before use, and delivered to the HPLC system at a flow rate of 1 mL/min. The detection was performed at 293 nm for CP and LV and at 214 nm for NAC. The total run time for the analysis was 15 min and the injection volume was 5 µL.
Preparation of standard solutions
Standard stock solutions of CP, LV, and NAC (1000 µg/mL) were prepared in the mobile phase. These stock solutions were then diluted with the mobile phase to obtain solutions within the concentration range of 5-400 µg/mL for CP, LV, and NAC.
Method validation
The HPLC method was validated as to specificity, linearity, sensitivity (limit of detection (LOD) and limit of quantitation (LOQ)), accuracy, precision (repeatability and reproducibility), and stability according to the ICH guidelines [27] .
Specificity
The specificity of the analytical method was assessed by injecting a drug-free mobile phase and Hank's Balanced Salt Solution (HBSS) (10 mM HEPES) (transport medium) into the HPLC system. HBSS (10 mM HEPES)
is often used as a transport buffer for cell cultures because it provides a buffering system and maintains the physiological pH range and osmotic balance of the culture medium. It is also a source of water, inorganic ions, and energy for cells.
Linearity
The linearity of the method was evaluated by spiking at least 6 different concentrations within the concentration range of 10-400 µg/mL for CP, LV, and NAC (six different series were prepared). Calibration curves for CP, LV, and NAC were constructed by plotting the peak areas of each compound against the corresponding nominal concentrations. Linearity of the analytical method was demonstrated by the calibration equation obtained from the calibration curve and the equation was characterized by intercept, slope, and determination coefficient.
Sensitivity
By determining the LODs and LOQs, the sensitivity of the method was assessed. LOD is described as the lowest amount of analyte in a sample that can be detected, and LOQ as the lowest amount of analyte in a sample that can be quantitatively determined with suitable accuracy and precision. The signal to noise ratios of 3:1 and 10:1 were taken as the LOD and LOQ, respectively.
Precision
Intra-and interday precision studies were carried out for assessment of the assay precision. Three different concentrations of compounds (10, 100, and 400 µg/mL for CP and LV; 10, 100, and 300 µg/mL for NAC)
within the calibration range were analyzed 6 consecutive days (interday) and 6 times within the same day (intraday) to determine the precision of the method. The relative standard deviations (RSDs) of intra-and interday studies were calculated for assessment of precision of the method.
Accuracy
Accuracy studies were carried out using 3 different concentrations of compounds (10, 100, and 400 µg/mL for CP and LV; 10, 100, and 300 µg/mL for NAC). Accuracies of the method were calculated as percentage of bias and percentage of recovery.
Stability
Stability studies of samples containing all compounds (CP, LV, and NAC) were performed for 24 h. All samples were stored at room temperature and then analyzed using the developed HPLC method. The results were compared with the initial values of the compounds.
Production of microparticulate DPIs
The details of the production and characterization of the microparticulate DPIs were published in our previous paper [27] . Briefly, LV solutions and CP suspensions (prepared using ball milling and high pressure homogenization methods) were obtained. The resulting suspensions or solutions were then spray-dried, either alone or with the addition of NAC solution. At the end of production, formulations containing CP were in crystalline form, whereas the formulations containing LV were amorphous. Aerodynamic parameters of manufactured formulations were evaluated by Andersen Cascade Impactor. Fine particle dose (< 5 µm), fine particle fraction (%) (< 5 µm), emitted dose, and mass median aerodynamic diameter results were 11. 
Content uniformity
In this study, four different DPI formulations (two of them containing only quinolones, and the other two containing combinations of the antibiotics with NAC) were developed and their content uniformities were tested using the developed HPLC method. The DPIs were dissolved in 25 mL of mobile phase for CP-containing formulations (CP DPI or CP-NAC DPI) and LV-containing formulations (LV DPI or LV-NAC DPI). The solutions were filtered and analyzed using the HPLC method to determine the amount of CP, LV, and NAC in DPIs.
Permeability
The Calu-3 cell line (human airway epithelial cells) was used to measure the permeability of the produced inhaler formulations as described in our previous work [28] . To evaluate permeabilities, cells were grown as liquid-covered culture (LCC) and air-interfaced culture (AIC). Seeding to ThinCert (0.4 µm, 1.13 cm 2 ) was performed in such a way that the density of the cells was 5 × 10 5 cells/cm 2 . The growth medium was changed every other day for 21 days to obtain the LCC. Growth medium at the apical side was removed 10 days after seeding to obtain the AIC, and then only the media at the basolateral sides were changed for another 10 days.
Raw CP, raw LV, and manufactured DPIs were applied as dry powders (formulations containing 3.7 mg CP (and 0.244 mg NAC) or 3.7 mg LV (and 0.211 mg NAC)) and as solutions in HBSS (10 mM HEPES) (formulations containing 0.65 mM CP (and 0.118 mM NAC) or 1.161 mM LV (and 0.184 mM NAC)). Samples were taken from basolateral sides after 2 h of incubation. Concentrations of CP, LV, and NAC in samples were detected using the developed method. Permeability (P app ; cm/s) data were obtained using Eq. (1).
P app = Rate of transport / (surface area × initial donor concentration) (1)
Statistical analysis
The data were analyzed using the Mann-Whitney U test. For this purpose, GraphPad Prism 6 was utilized.
The difference between the results was considered significant at P < 0.05.
Results and discussion
Optimization of chromatographic conditions
An HPLC method was validated for simultaneous determination of CP, LV, and NAC for content uniformity and permeability studies. To determine the amount of NAC and antibiotics in the obtained samples, the method developed by Chamseddin and Jira [12] was adapted. The published method was only tested for chromatographic behavior of three fluoroquinolone antibiotics and was not applied for any pharmaceutical or biological samples. They tested different stationary phases and mobile phase variables such as methanol content, pH, and buffer concentration. Finally, they suggested a C18 (100 × 4.6 mm, 2.4 µm) HPLC column and an isocratic mobile phase consisting of MeOH/25 mM phosphate buffer 28/72 (v/v) at pH 3 and flow rate 1 mL/min. There was no validation study for the method, and the selectivity of the method was not tested. However, in our study, NAC was analyzed in addition to CP and LV. Since CP, LV, and NAC, as active pharmaceutical substances, are frequently formulated together, the ability to analyze these three substances at the same time with a single method is an important innovation that accelerates pharmaceutical studies, and also their monitoring in pharmaceutical formulation during stability studies, which is an obligatory regulatory requirement. In addition, another difference and advantage of our study is that the method of analysis has been tested in DPI and the transport media where permeability studies were carried out by Caco-2 cell culture method. The initial optimization studies started with the chromatographic conditions suggested by Chamseddin and Jira, except for the length and particle size of the column, which were different from the original method.
In our study, an Inertsil ODS-3V C18 column (250 × 4.6 mm 5 µm; Japan) was used for the separation of NAC and antibiotics. Therefore, the system suitability and selectivity of the method were initially tested for NAC and antibiotics. Moreover, the detection of active pharmaceutical ingredients was performed at 214 nm for NAC and at 293 nm for CP and LV in order to increase the sensitivity of the method. Additionally, column temperature was set to 40°C to avoid any related temperature changes. Because of its simplicity, stable baseline, and unvarying response factor, isocratic elution of the mobile phase was used for analysis. Increasing flow rate decreases retention times, but also brings closer peaks of substances. Therefore, 1 mL/min flow rate was chosen for the analysis. An injection volume of 5 µL was adequate to analyze the compounds.
System suitability parameters were tested to show that the system was working accurately during the analysis. The fact that the capacity factor (k) is between 1 and 10 indicates that the method has optimum separation ability [27] . Determined capacity factor (k) values were 4.41, 3.10, and 3.02 for CP, LV, and NAC, respectively, indicating that these values were within the acceptable limits. The theoretical plate numbers were 5196, 6728, and 6471 for CP, LV, and NAC, respectively, which were in the acceptable limit of N ≥ 2000. The tailing factors, which were also in the acceptable limit (T ≤ 2), were obtained as 1.08, 0.92, and 1.10 for CP, LV, and NAC, respectively. Overall, these results indicate that the validated method fulfilled the recommended system suitability parameters for the simultaneous analysis of CP with NAC and of LV with NAC.
Method validation
Selectivity
The ability to differentiate and measure the target analyte in the presence of other components in the sample indicates the selectivity of the analytical method [27] . Following separate injection of 25 mM KH 2 PO 4 (pH 3.0) and methanol (72:28, v/v) (mobile phase) and HBSS (transport medium) into the HPLC column, there was no interfering peak at the retention times of CP (13.516), LV (10.253), and NAC (4.022) (Figures 1 and 2) . Based on the obtained chromatograms, the validated method was considered to be selective.
Linearity
The high correlation between the concentrations of an analyte and the representative peak areas shows the linearity of an analytical method. Calibration curves of the compounds were formed by plotting the peak areas of each compound against the corresponding concentrations. Regression analysis of the calibration curves showed linearity between peak areas and the corresponding CP, LV, and NAC concentrations. Although there was no interference from the transport medium (Figures 1 and 2) , the calibration curves were obtained for the mobile phase and transport medium (HBSS). Since there was no significant difference between the calibration curves, only linearity data in the mobile phase for all compounds were demonstrated ( Table 1) . *The regression equation is expressed as y = ax + b, where x is the concentration (mg/mL) and y is the peak area.
Sensitivity
The LOD values were 0.098 µg/mL for CP, 0.049 µg/mL for LV, and 0.487 µg/mL for NAC. The LOQ values were 0.328 µg/mL for CP, 0.165 µg/mL for LV, and 1.624 µg/mL for NAC (Table 1 ). All these results imply that this analytical method is sensitive enough for determination of CP, LV, and NAC in content uniformity and permeability samples.
Precision and accuracy
Precision represents the degree of proximity between successive measurements under the same analytical conditions. Table 2 demonstrates the intraday and interday precision data determined at 3 different concentrations (low, medium, and high). The RSD values estimated for the intraday and interday precision of the assay were lower than 2%, demonstrating that the precision of the validated HPLC method was acceptable. Accuracy is the measure of how close the experimental value is to the true value. For all substances and concentrations, recovery (%) values were between 99% and 101%, indicating that the experimental values are close enough to actual values (Table 2) .
Stability
To demonstrate the stability of the drugs during analysis, CP, LV, and NAC solutions prepared at certain concentrations were examined. The stability was evaluated for 24 h since the analysis time did not exceed 24 h. The obtained data showed that the concentration changes in CP, LV, and NAC solutions were statistically insignificant during this period (P >0.05). These results indicate that our substances were stable during the time analysis period (Table 3) .
Content uniformity
The manufactured formulations were evaluated for CP, LV, and NAC contents using the validated HPLC method. The content uniformity results are given in Table 4 and HPLC chromatograms of CP-NAC-and LV-NAC-containing DPIs are shown in Figure 3 . 
Permeability
To investigate the permeability behavior of antibiotics from DPIs, Calu-3 cells (lung adenocarcinoma cell line)
were used. As a result of the permeability study, it was observed that with dry powder application, lower and more variable permeability values were obtained than those of the solution application. The only condition in which the presence of the mucolytic changed the permeability of the antibiotic was when the formulations were applied as powder under LCC conditions. Moreover, as expected, CP had lower permeability than LV. Permeability data are shown in Table 5 . HPLC chromatograms of CP-NAC-and LV-NAC-containing DPIs are shown in Figure 4 . 
Conclusions
NAC is a frequently used mucolytic agent in formulations in combination with CP and LV antibiotics. In this study, the quantification of these 3 drugs was carried out by an HPLC method that was selective, accurate, sensitive, reliable, and reproducible. With the validated HPLC method, simultaneous CP, LV, and NAC determination was successfully performed in the produced microparticulate DPIs. The method was successfully applied to content uniformity and permeability samples to determine all of these compounds. The validated HPLC method can be used not only for DPI dosage forms but also in formulations containing CP, LV, and NAC in different dosage forms.
